Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model
Abstract
No abstract availableKeywords
Funding Information
- INOVIO Pharmaceuticals
- National Institutes of Health (U19 AI078675, R01 AI092843, U19 AI109646)
This publication has 34 references indexed in Scilit:
- Hydrodynamic immunization leads to poor CD8 T-cell expansion, low frequency of memory CTLs and ineffective antiviral protectionCancer Gene Therapy, 2013
- T‐cell‐inducing vaccines – what’s the futureImmunology, 2011
- IL‐33 synergizes with TCR and IL‐12 signaling to promote the effector function of CD8+ T cellsEuropean Journal of Immunology, 2011
- A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challengeVaccine, 2011
- Profound early control of highly pathogenic SIV by an effector memory T-cell vaccineNature, 2011
- Vaccine Adjuvants: Putting Innate Immunity to WorkImmunity, 2010
- Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challengeNature Medicine, 2009
- Inflammation Directs Memory Precursor and Short-Lived Effector CD8+ T Cell Fates via the Graded Expression of T-bet Transcription FactorImmunity, 2007
- Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infectionJournal of Experimental Medicine, 2007
- Lineage relationship and protective immunity of memory CD8 T cell subsetsNature Immunology, 2003